New method improves detection of disease changes.
Using new MRI method, providers can identify damage to white brain matter in patients with multiple sclerosis that has previously appeared normal, according to new research findings.
By using a novel software solution, developed by MRI software solution company Random Walk Imaging (RWI), investigators showed that enhancing MRI images to the microscopic level can reveal a greater level of detail about damage to the brain than was previously possible. This data can help researchers determine a stronger correlation to disease clinical and cognitive scores, the team said.
“The data from this study provide convincing evidence that microscopic mapping substantially advances the assessment of cerebral white matter degeneration in multiple sclerosis,” said Tim Dyrby, Ph.D., the associate professor who led the study at the Danish Research Center for Magnetic Resonance, Copenhagen University Hospital Hvidovre and Technical University of Denmark. “This information, which cannot be seen using standard MRI techniques, such as diffusion tensor imaging (DTI), could provide a unique opportunity for precision imaging, leading to a more accurate diagnosis both in MS and other degenerative CNS diseases.”
The team published their results in Brain Communications.
Typically, MRI images are used to detect the damage multiple sclerosis causes to the nerve myelin and the central nervous system. Fractional anisotropy, which is mapped with DTI on the MRI scanner, is also used to measure the white matter degeneration caused by multiple sclerosis. However, because FA also picks up on the different orientations of white matter fibers, the actual detection of disease-related damage can be distorted.
Courtesy: Brain Communications
To correct this problem, RWI developed a new DTI MRI methodology that can produce a microscopic FA (mFA) metric that is not affected by white matter orientation. Researchers tested the methodology by comparing normal-appearing white matter from 26 patients who had relapsing-remitting multiple sclerosis, 14 patients with primary progressive multiple sclerosis, and 27 age-matched healthy patients. They used standard FA and mFA mapping with RWI’s tool.
According to the study results, the mean standard FA and mFA of normal-appearing white matter was significantly reduced in multiple sclerosis patients compared to the healthy participants. The mFA, though, did a significantly better job in detecting disease-related white-matter alternations in patients with both types of multiple sclerosis.
The researchers said the mean mFA reduction – which represented degenerated fibers – also showed:
In comparison, standard mean FA was unable to distinguish any of these relationships between normal-appearing white matter microstructure and clinical, cognitive, or structural measures, the team reported.
Ultimately, the team said, they hoped these findings will be able to change and improve the clinical services available for patients who have multiple sclerosis.
“These findings are highly interesting,” said Finn Sellebjerg, M.D., Ph.D., neurology professor at the University of Copenhagen and head of the Danish Multiple Sclerosis Center. “I hope that this new diffusion MRI analysis will prove valuable in diagnosing and monitoring treatment of multiple sclerosis in the future.”
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.